SMITH & NEPHEW PLC
11 November 2026
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument | Smith & Nephew plc ordinary shares of USD 0.20 each |
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Purchase of ordinary shares through the Company’s Dividend Re-Investment Plan following the 2026 interim dividend payment on 6 November 2026. |
Date of Transaction | 2026 – 11 – 06 |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) | Director / PDMR | Price | Volume | Aggregated information |
Deepak Nath (Chief Executive Officer) | Director | 11.676693 | 4354.91595 | N/A Single Transaction |
Scott Schaffner (President, Sports Medicine) | PDMR | 11.676693 | 1400.18596 | N/A Single Transaction |
Paul Connolly (President, Global Operations) | PDMR | 11.676693 | 775.61555 | N/A Single Transaction |
Ajay Dhankhar (Chief Strategy & Corporate Development Officer) | PDMR | 11.676693 | 210.78942 | N/A Single Transaction |
Alison Parkes (Chief Compliance Officer) | PDMR | 11.676693 | 100.10139 | N/A Single Transaction |
Philip Horner
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
LEI: 213800ZTMDN8S67S1H61
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.